Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX-2337 plus PLD in Recurrent Ovarian Cancer
NCT01666444Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2012
- Primary completion
- Jul 2016
- Countries
- 1
01
Overview
A Phase 2 trial of motolimod in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Celgene Corporation. Started Oct 2012; status: completed.
02
Drugs
motolimod
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01666444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666444.